Next Article in Journal
Genomic and Metabolomic Analyses of Natural Products in Nodularia spumigena Isolated from a Shrimp Culture Pond
Next Article in Special Issue
Chronodisruption: A Poorly Recognized Feature of CKD
Previous Article in Journal
Human Mycotoxin Biomonitoring: Conclusive Remarks on Direct or Indirect Assessment of Urinary Deoxynivalenol
Previous Article in Special Issue
Molecular and Cellular Mechanisms that Induce Arterial Calcification by Indoxyl Sulfate and P-Cresyl Sulfate
Open AccessReview

Should We Consider the Cardiovascular System While Evaluating CKD-MBD?

1
University Department of Nephrology, Faculty of Medicine, University of Medicine Tirana, Tirana 1001, Albania
2
Institute of Anatomy, University of Zurich, Zurich 8057, Switzerland
3
University Department of Nephrology, Medical Faculty, University of Skopje, Skopje 1000, North Macedonia
*
Author to whom correspondence should be addressed.
Toxins 2020, 12(3), 140; https://doi.org/10.3390/toxins12030140 (registering DOI)
Received: 6 January 2020 / Revised: 12 February 2020 / Accepted: 20 February 2020 / Published: 25 February 2020
(This article belongs to the Special Issue Comorbidities in Chronic Kidney Disease (CKD))
Cardiovascular (CV) disease is highly prevalent in the population with chronic kidney disease (CKD), where the risk of CV death in early stages far exceeds the risk of progression to dialysis. The presence of chronic kidney disease-mineral and bone disorder (CKD-MBD) has shown a strong correlation with CV events and mortality. As a non-atheromatous process, it could be partially explained why standard CV disease-modifying drugs do not provide such an impact on CV mortality in CKD as observed in the general population. We summarize the potential association of CV comorbidities with the older (parathyroid hormone, phosphate) and newer (FGF23, Klotho, sclerostin) CKD-MBD biomarkers. View Full-Text
Keywords: chronic kidney disease; uremic cardiopathy; left ventricular hypertrophy; phosphate; PTH; FGF23; klotho; sclerostin chronic kidney disease; uremic cardiopathy; left ventricular hypertrophy; phosphate; PTH; FGF23; klotho; sclerostin
Show Figures

Figure 1

MDPI and ACS Style

Rroji, M.; Figurek, A.; Spasovski, G. Should We Consider the Cardiovascular System While Evaluating CKD-MBD? Toxins 2020, 12, 140.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop